Loading...
Market
What will be the outcome of Phase I/II clinical trial of REC-1245 by December 31, 2025?
2
Resolution / Starting Odds
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Clinical trial results published by Recursion Pharmaceuticals or FDA announcements
Story
Recursion's AI-Derived REC-1245 Gets FDA Clearance; First-in-Class RBM39 Degrader for Solid Tumors, Lymphoma
Oct 2, 2024, 12:20 PM
Recursion Pharmaceuticals (RXRX) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for REC-1245, a potential first-in-class RBM39 degrader intended for biomarker-enriched solid tumors and lymphoma. This marks the company's first program to combine its end-to-end suite of AI-enabled active learning modules, moving from target identification to IND enabling studies in under 18 months, more than twice as fast as industry standards. The FDA clearance paves the way for Recursion to initiate a Phase I/II clinical trial of REC-1245.
View original story
Similar markets
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Yes • 50%
No • 50%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative results • 25%
Trial discontinued • 25%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Start of Phase 3 trial • 33%
FDA approval • 33%
Partnership announcement • 33%